- Tender offer statement by Third Party (SC TO-T)
03 Décembre 2008 - 11:20PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
SCHEDULE TO
Tender
Offer Statement under Section 14(d)(1) or 13(e)(1) of
the Securities Exchange Act of 1934
MEMORY
PHARMACEUTICALS CORP.
(Name of Subject
Company)
900 NORTH POINT ACQUISITION
CORPORATION
HOFFMANN-LA ROCHE
INC.
(Names of Filing
Persons Offeror)
Common Stock, Par Value $0.001
Per Share
(Title of Class of
Securities)
58606R403
(Cusip Number of Class of
Securities)
Frederick C. Kentz III
Hoffmann-La Roche
Inc.
340 Kingsland Street
Nutley, New Jersey
07110
Telephone:
(973) 235-5000
(Name, Address and Telephone
Number of Person Authorized to Receive Notices
and Communications on Behalf of
Filing Persons)
Copies to:
Marc O. Williams
Davis Polk &
Wardwell
450 Lexington Avenue
New York, New York
10017
Telephone:
(212) 450-4000
CALCULATION OF FILING
FEE
|
|
|
|
Transaction Valuation*
|
|
|
Amount of Filing Fee**
|
$50,435,251.01
|
|
|
$1,982.11
|
|
|
|
|
|
|
|
*
|
|
Estimated for purposes of
calculating the filing fee only. This amount assumes the
purchase of all 82,243,050 shares of common stock of Memory
Pharmaceuticals Corp. outstanding as of November 20, 2008
and options outstanding as of November 20, 2008 with
respect to 1,708,030 shares of common stock of Memory
Pharmaceuticals Corp.
|
|
**
|
|
The amount of the filing fee is
calculated in accordance with
Rule 0-11
of the Securities Exchange Act of 1934, as amended, by
multiplying the transaction valuation by 0.00003930.
|
|
|
|
o
|
|
Check box if any part of the fee is offset as provided by Rule
0-11(a)(2) and identify the filing with which the offsetting fee
was previously paid. Identify the previous filing by
registration statement number, or the Form or Schedule and the
date of its filing.
|
|
|
|
|
|
|
|
Amount Previously Paid:
|
|
Not applicable.
|
|
Filing Party:
|
|
Not applicable.
|
|
|
|
|
|
|
|
Form or Registration No.:
|
|
Not applicable.
|
|
Date Filed:
|
|
Not applicable.
|
|
|
|
|
|
|
|
|
|
|
o
|
|
Check the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions
to which the statement relates:
|
|
|
þ
|
|
third-party tender offer subject to
Rule 14d-1.
|
o
|
|
issuer tender offer subject to
Rule 13e-4.
|
o
|
|
going-private transaction subject to
Rule 13e-3.
|
o
|
|
amendment to Schedule 13D under
Rule 13d-2.
|
Check the following box if the filing is a final amendment
reporting the results of the tender
offer.
o
Items 1
through 9, and Item 11.
This Tender Offer Statement on Schedule TO (the
Schedule TO
) relates to the offer by 900
North Point Acquisition Corporation, a Delaware corporation and
a wholly owned subsidiary of Hoffmann-La Roche Inc, a New
Jersey Corporation, to purchase all outstanding shares of common
stock, par value $0.001 per share (the
Shares
) of Memory Pharmaceuticals Corp., a
Delaware corporation, at $0.61 per Share, net to the seller in
cash, without interest and less applicable withholding taxes,
upon the terms and subject to the conditions set forth in the
Offer to Purchase, dated December 3, 2008 (the
Offer to Purchase
), and in the related Letter
of Transmittal, copies of which are attached hereto as Exhibits
(a)(1)(i) and (a)(1)(ii), respectively (which, together with any
amendments or supplements thereto, collectively constitute the
Offer
).
The information set forth in the Offer to Purchase, including
all schedules thereto, is hereby expressly incorporated herein
by reference in response to all of the items of this
Schedule TO, except as otherwise set forth below.
|
|
Item 10.
|
Financial
Statements.
|
Not applicable.
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
(a)(1)(i)
|
|
|
Offer to Purchase dated December 3, 2008.
|
|
(a)(1)(ii)
|
|
|
Letter of Transmittal (including Guidelines for Certification of
Taxpayer Identification Number on Substitute
Form W-9).
|
|
(a)(1)(iii)
|
|
|
Notice of Guaranteed Delivery.
|
|
(a)(1)(iv)
|
|
|
Letter to Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees.
|
|
(a)(1)(v)
|
|
|
Letter to Clients for use by Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees.
|
|
(a)(1)(vi)
|
|
|
Summary Advertisement dated December 3, 2008.
|
|
(a)(5)(i)
|
|
|
Press Release issued by Roche Holding Ltd, dated
November 25, 2008.*
|
|
(b)
|
|
|
Not applicable.
|
|
(c)
|
|
|
Not applicable.
|
|
(d)(1)
|
|
|
Agreement and Plan of Merger, dated as of November 25,
2008, among Memory Pharmaceuticals Corp., Hoffmann-La Roche
Inc. and 900 North Point Acquisition Corporation (incorporated
by reference to the
Form 8-K
filed by Memory Pharmaceuticals Corp. on November 25, 2008).
|
|
(d)(2)
|
|
|
Tender and Support Agreement, dated as of November 25,
2008, among Hoffmann-La Roche Inc. and certain stockholders
listed on the signature pages thereto (incorporated by reference
to the
Schedule 14D-9
filed by Memory Pharmaceuticals Corp. on December 3, 2008).
|
|
(d)(3)
|
|
|
Confidentiality Agreement, dated October 29, 2008, between
F. Hoffmann-La Roche Ltd and Memory Pharmaceuticals
Corp. (incorporated by reference to the
Schedule 14D-9
filed by Memory Pharmaceuticals Corp. on December 3, 2008).
|
|
(e)
|
|
|
Not applicable.
|
|
(f)
|
|
|
Not applicable.
|
|
(g)
|
|
|
Not applicable.
|
|
(h)
|
|
|
Not applicable.
|
SIGNATURES
After due inquiry and to the best knowledge and belief of the
undersigned, each of the undersigned certify that the
information set forth in this statement is true, complete and
correct.
Date: December 3, 2008
900 NORTH POINT ACQUISITION CORPORATION
By:
/s/ Frederick
C. Kentz III
Name: Frederick C. Kentz III
Title: President
HOFFMANN-LA ROCHE INC.
By:
/s/ Frederick
C. Kentz III
Name: Frederick C. Kentz III
Title: Vice President
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
(a)(1)(i)
|
|
|
Offer to Purchase dated December 3, 2008.
|
|
(a)(1)(ii)
|
|
|
Letter of Transmittal (including Guidelines for Certification of
Taxpayer Identification Number on Substitute
Form W-9).
|
|
(a)(1)(iii)
|
|
|
Notice of Guaranteed Delivery.
|
|
(a)(1)(iv)
|
|
|
Letter to Brokers, Dealers, Commercial Banks, Trust Companies
and Other Nominees.
|
|
(a)(1)(v)
|
|
|
Letter to Clients for use by Brokers, Dealers, Commercial Banks,
Trust Companies and Other Nominees.
|
|
(a)(1)(vi)
|
|
|
Summary Advertisement dated December 3, 2008.
|
|
(a)(5)(i)
|
|
|
Press Release issued by Roche Holding Ltd, dated November 25,
2008.*
|
|
(b)
|
|
|
Not applicable.
|
|
(c)
|
|
|
Not applicable.
|
|
(d)(1)
|
|
|
Agreement and Plan of Merger, dated as of November 25,
2008, among Memory Pharmaceuticals Corp., Hoffmann-La Roche
Inc. and 900 North Point Acquisition Corporation (incorporated
by reference to the
Form 8-K
filed by Memory Pharmaceuticals Corp. on November 25, 2008).
|
|
(d)(2)
|
|
|
Tender and Support Agreement, dated as of November 25,
2008, among Hoffmann-La Roche Inc. and certain stockholders
listed on the signature page thereto (incorporated by reference
to the
Schedule 14D-9
filed by Memory Pharmaceuticals Corp. on December 3, 2008).
|
|
(d)(3)
|
|
|
Confidentiality Agreement, dated October 29, 2008, between
F. Hoffmann-La Roche Ltd and Memory Pharmaceuticals
Corp. (incorporated by reference to the
Schedule 14D-9
filed by Memory Pharmaceuticals Corp. on December 3, 2008).
|
|
(e)
|
|
|
Not applicable.
|
|
(f)
|
|
|
Not applicable.
|
|
(g)
|
|
|
Not applicable.
|
|
(h)
|
|
|
Not applicable.
|
Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Graphique Historique de l'Action
De Juil 2024 à Juil 2024
Memory Pharmaceuticals Corp (MM) (NASDAQ:MEMY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024